JUPITER NEUROSCIENCES, INC.
About JUPITER NEUROSCIENCES, INC.
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $21.8K
- Net income
- -$8.6M
- Total assets
- $5.6M
- Market cap
- $10.5M
- Operating margin
- -40873.2%
- Net margin
- -39662.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $21.8K
- Operating expenses
- $8.9M
- Operating income
- -$8.9M
- Net income
- -$8.6M
- EPS (basic)
- $-0.25
- EPS (diluted)
- $-0.25
Balance sheet
- Total assets
- $5.6M
- Current assets
- $4.8M
- Total liabilities
- $7.4M
- Current liabilities
- $7.4M
- Shareholders’ equity
- -$1.8M
Cash flow
- Operating cash flow
- -$5.4M
- Investing cash flow
- -$19.8K
- Financing cash flow
- $5.4M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $10.5M
- EPS (diluted)
- $-0.25
- Shares outstanding
- 45.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 3, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $8.6M in FY2025.
- Trading 92% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review JUPITER NEUROSCIENCES, INC..
Write a review
News about JUPITER NEUROSCIENCES, INC.
News & sentiment via Polygon.io
